UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 6, 2014
MMRGLOBAL, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE |
|
000-51134 |
|
33-0892797 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
|
|
4401 WILSHIRE BLVD., SUITE 200
LOS ANGELES, CA 90010 |
(Address of Principal Executive Offices)
(Zip Code) |
(310) 476-7002
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On October 6, 2014, MMRGlobal, Inc. (the "Company") issued a press release updating its stockholders about the Company's
results of operations for the third quarter ending September 30, 2014. A copy of the Company's press release is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description |
99.1 |
MMRGlobal, Inc. press release dated October 6, 2014. |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MMRGLOBAL, INC.
|
October 7, 2014 |
|
By: /s/ Robert H. Lorsch
Robert H. Lorsch
Chief Executive Officer
|
EXHIBIT INDEX
Exhibit 99.1
FOR IMMEDIATE RELEASE
MMRGlobal to Report Third Quarter Revenue Exceeding Biggest Year in Company History
LOS ANGELES, CA (October 6, 2014) - MMRGlobal, Inc.
(OTC: MMRF) ("MMR" or the "Company") today announced that it will report third quarter
revenues from all sources in excess of total revenues from its biggest year. The Health Information Technology and Biotechnology Company
will report substantially more revenue than the $1.420 million reported from the entire calendar year of 2011, previously the biggest year in the
Company's history and which the Company has received in cash. Additional information will be contained in the Company's quarterly report on
Form 10-Q for the period ended September 30, 2014. According to MMRGlobal CEO Robert H. Lorsch,
"In a letter to shareholders earlier this year, the Company projected that 2014 would be `our year' and at this time it appears that it
is." The Company licenses and sells worldwide Health Information Technology and Biotech intellectual property rights, including
international patents, vaccine and patient samples and anti-CD20 monoclonal antibodies.
Although MMR's primary focus is as a provider and licensor of Health IT
products and
services, the Company also has a growing list of biotech patents. These include cancer-fighting anti-CD20 monoclonal antibody assets under
the title, "Antibodies and Methods For Making and Using Them," issued in the United States, Mexico, Australia and South Korea. Additional
patents for the Company's antibody technology are also pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan
and Korea. The Company also holds additional patents pertaining to a B-cell idiotype vaccine worldwide.
Through its wholly owned subsidiary, MyMedicalRecords, Inc., the Company sells Health IT products and services including its
MyMedicalRecords Personal Health Record
and other patented health information technologies
to consumers, physicians, hospitals, surgical centers and other healthcare professionals, as well as retailers, employers and professional
organizations. MMR also offers its MMRPro document management and imaging system for healthcare
professionals
, and
MyEsafeDepositBox, which
provides an online site to securely store legal, financial, insurance and other important documents, as well as medical and personal health
information.
MyMedicalRecords is a practicing entity whose Health IT patent portfolio currently consists of 13 issued U.S. patents, 17 pending U.S.
applications, and numerous issued patents and pending applications in other countries or regional authorities of commercial interest including
Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel and Europe. MMR's U.S. patents include
U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537;
8,768,725 and 8,775,212, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. The most recently
issued U.S. patent, U.S. Patent No. 8,775,212, represents MMR's first Clinical Trials patent and includes 18 claims directed to methods and
systems that provide for self-reporting being used to create Electronic Health Records for purposes including Clinical Trials.
2/
About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online
Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers,
insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important
documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is
built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system
using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a
user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an
easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and
data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn
more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of
MMR's products and services at www.mmrtheater.com. Follow us on Facebook.com/MMRGlobal and Twitter.com/mmrglobal.
Forward-Looking Statements
All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on
MMR's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR's actual results to
be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words
such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks,
uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual
property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR's ability to develop, license and
monetize its patents in the portfolio for both MMR's health IT and biotechnology IP assets; the timing of milestone payments in connection with
licensing its IP; reliance upon the successful operations of its business partners in selling MMR's products and services; MMR's ability to obtain
necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market
competition in the area of electronic records in clinical trials. These factors and others are described in more detail in MMR's public filings with
the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in MMR's Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR's website (www.mmrglobal.com) under the heading "Investor Relations." MMR is providing this information
as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.
###
CONTACT:
Michael Selsman
Public Communications Co.
(310) 922-7033
ms@publiccommunications.biz